AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
262.71B
Market cap262.71B
Price-Earnings ratio
25.26
Price-Earnings ratio25.26
Dividend yield
1.86%
Dividend yield1.86%
Average volume
2.68M
Average volume2.68M
High today
$173.22
High today$173.22
Low today
$167.79
Low today$167.79
Open price
$170.12
Open price$170.12
Volume
2.48M
Volume2.48M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$142.98
52 Week low$142.98

Stock Snapshot

The current AstraZeneca(AZN) stock price is $169.32, with a market capitalization of 262.71B. The stock trades at a price-to-earnings (P/E) ratio of 25.26 and offers a dividend yield of 1.86%.

As of 2026-07-27, AstraZeneca(AZN) stock has fluctuated between $167.79 and $173.22. The current price stands at $169.32, placing the stock +0.9% above today's low and -2.3% off the high.

The AstraZeneca(AZN)'s current trading volume is 2.48M, compared to an average daily volume of 2.68M.

During the past year, AstraZeneca(AZN) stock moved between $142.98 at its lowest and $212.71 at its peak.

During the past year, AstraZeneca(AZN) stock moved between $142.98 at its lowest and $212.71 at its peak.

AZN News

The Wall Street Journal 2h
Health Care Roundup: Market Talk

Yves Herman / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Health Care Roundup: Market Talk
TipRanks 2h
AstraZeneca’s MONTEROSA Study Tracks Real World Outcomes for STRIDE in Liver Cancer

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confi...

TipRanks 2h
AstraZeneca’s AZD2389 Liver Fibrosis Study Reaches Key Early Milestone

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident...

Analyst ratings

77%

of 31 ratings
Buy
77.4%
Hold
16.1%
Sell
6.5%

More AZN News

Simply Wall St 2h
AstraZeneca Pressure Puts Krystal Biotech, TG Therapeutics And Gilead Stocks In Focus

Healthcare investors are watching AstraZeneca closely after fresh comments about operating at Chinese speed, reaffirming a 2030 sales goal of $80b and reporting...

AstraZeneca Pressure Puts Krystal Biotech, TG Therapeutics And Gilead Stocks In Focus
Benzinga 4h
Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 400 points on Monday. Following the market opening Monday, the Dow traded up...

Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings
TipRanks 4h
Omeros up 11% to $10.89 after AstraZeneca study failure

10:11 EDT Omeros (OMER) up 11% to $10.89 after AstraZeneca (AZN) study failure Published first on TheFly – the ultimate source for real-time, market-moving bre...

Benzinga 5h
Pipeline Speed Bump Doesn't Shake AstraZeneca's $80 Billion Revenue Ambition

AstraZeneca Beats Earnings Estimates, Misses Revenue Expectations The company posted revenue of $15.384 billion, up 6% year over year, or 5% at constant curren...

Pipeline Speed Bump Doesn't Shake AstraZeneca's $80 Billion Revenue Ambition
TipRanks 8h
AstraZeneca: Buy Rating Reiterated as Strong Q2, Robust Pipeline Support Unchanged 16,500 GBp Price Target

Analyst Sachin Jain from Bank of America Securities reiterated a Buy rating on AstraZeneca and keeping the price target at p16,500.00. Unlock powerful investin...

Nasdaq 10h
AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View

(RTTNews) - British drug major AstraZeneca PLC reported Monday lower pre-tax pofit in its second quarter mainly on lower tax expenses, while earnings per share...

AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View
The Wall Street Journal 11h
AstraZeneca Posts Sales Growth on Oncology Strength

AstraZeneca reiterated its 2030 revenue target after a clinical trial failure earlier this month. Michael Nagle / Bloomberg News AstraZeneca AZN -0.14 %decreas...

AstraZeneca Posts Sales Growth on Oncology Strength

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.